What are the economic barriers of antibiotic R&D and how can we overcome them?

被引：42
作者：
Renwick, Mathew [1 ]
Mossialos, Elias [1 ]
机构：
[1] London Sch Econ & Polit Sci, Dept Hlth Policy, Houghton St, London WC2A 2AE, England
来源：
EXPERT OPINION ON DRUG DISCOVERY | 2018年 / 13卷 / 10期
关键词：
Antibiotics; drug discovery; drug development; incentives; antimicrobial resistance; health policy; DISCOVERY; CHALLENGES; RESISTANCE;
D O I：
10.1080/17460441.2018.1515908
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：889 / 892
页数：4
相关论文
共 25 条
[1]  
[Anonymous], SCI ROADM ANT DISC
[2]  
[Anonymous], 2018, Becker's Hospital Review
[3]  
[Anonymous], 2015, SECURING NEW DRUGS F
[4]   A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility [J].
Brogan, David M. ;
Mossialos, Elias .
GLOBALIZATION AND HEALTH, 2016, 12
[5]   Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline [J].
Brogan, David M. ;
Mossialos, Elias .
SOCIAL SCIENCE & MEDICINE, 2016, 151 :167-172
[6]   Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model [J].
Brogan, David M. ;
Mossialos, Elias .
GLOBALIZATION AND HEALTH, 2013, 9
[7]   Antibiotics in the clinical pipeline at the end of 2015 [J].
Butler, Mark S. ;
Blaskovich, Mark A. T. ;
Cooper, Matthew A. .
JOURNAL OF ANTIBIOTICS, 2017, 70 (01) :3-24
[8]  
Chorzelski S, 2015, BREAKING WALL ENHANC
[9]   Alternatives to antibiotics-a pipeline portfolio review [J].
Czaplewski, Lloyd ;
Bax, Richard ;
Clokie, Martha ;
Dawson, Mike ;
Fairhead, Heather ;
Fischetti, Vincent A. ;
Foster, Simon ;
Gilmore, Brendan F. ;
Hancock, Robert E. W. ;
Harper, David ;
Henderson, Ian R. ;
Hilpert, Kai ;
Jones, Brian V. ;
Kadioglu, Aras ;
Knowles, David ;
Olafsdottir, Sigridur ;
Payne, David ;
Projan, Steve ;
Shaunak, Sunil ;
Silverman, Jared ;
Thomas, Christopher M. ;
Trust, Trevor J. ;
Warn, Peter ;
Rex, John H. .
LANCET INFECTIOUS DISEASES, 2016, 16 (02) :239-251
[10]  
DRIVE-AB, 2018, REV ANT PIP STIM INN
123